Loading clinical trials...
Loading clinical trials...
The Effects of High-dose Salbutamol on Anaerobic Cycling Power
Athletes using inhaled β2-adrenoreceptor agonists (IBAs) win a disproportionate number of medals. However, most previous research has shown that β2 agonists do not improve exercise performance in either asthmatic or non-asthmatic athletes. Although the majority of these studies do not show an ergogenic effect, the small number of studies with extended exercise bouts (\~60 minutes) do show an advantage. The investigators believe that a controlled yet sport-specific exercise protocol will elucidate this ergogenic effect. Because IBAs may have different effects on these two groups of athletes, the investigators will measure exercise performance in both female and male elite cyclists. The investigators hypothesize that athletes will perform better during a combination steady-state/sprint exercise task following salbutamol administration.
Age
19 - 40 years
Sex
ALL
Healthy Volunteers
Yes
University of British Columbia, Environmental Physiology Laboratory
Vancouver, British Columbia, Canada
Start Date
January 1, 2015
Primary Completion Date
November 1, 2015
Completion Date
August 1, 2016
Last Updated
November 10, 2016
20
ACTUAL participants
Cycling Exercise
OTHER
Lead Sponsor
University of British Columbia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions